IDEAS home Printed from https://ideas.repec.org/a/gam/jijerp/v17y2020i19p7247-d423553.html
   My bibliography  Save this article

The Impact of HMGB1 Polymorphisms on Prostate Cancer Progression and Clinicopathological Characteristics

Author

Listed:
  • Ying-Erh Chou

    (School of Medicine, Chung Shan Medical University, Taichung 402, Taiwan
    Institute of Medicine, Chung Shan Medical University, Taichung 402, Taiwan
    Department of Medical Research, Chung Shan Medical University Hospital, Taichung 402, Taiwan)

  • Po-Jen Yang

    (School of Medicine, Chung Shan Medical University, Taichung 402, Taiwan
    Institute of Medicine, Chung Shan Medical University, Taichung 402, Taiwan
    Department of Family and Community Medicine, Chung Shan Medical University Hospital, Taichung 402, Taiwan)

  • Chia-Yen Lin

    (Institute of Medicine, Chung Shan Medical University, Taichung 402, Taiwan
    Division of Urology, Department of Surgery, Taichung Veterans General Hospital, Taichung 407, Taiwan)

  • Yen-Yu Chen

    (School of Medical Applied Chemistry, Chung Shan Medical University, Taichung 402, Taiwan)

  • Whei-Ling Chiang

    (School of Medical Laboratory and Biotechnology, Chung Shan Medical University, Taichung 402, Taiwan)

  • Pei-Xuan Lin

    (School of Medical Laboratory and Biotechnology, Chung Shan Medical University, Taichung 402, Taiwan)

  • Zih-Yun Huang

    (School of Medical Laboratory and Biotechnology, Chung Shan Medical University, Taichung 402, Taiwan)

  • Matthew Huang

    (White Oaks Secondary School, Oakville, ON L6H 1Z5, Canada)

  • Yung-Chuan Ho

    (Department of Medical Research, Chung Shan Medical University Hospital, Taichung 402, Taiwan
    School of Medical Applied Chemistry, Chung Shan Medical University, Taichung 402, Taiwan)

  • Shun-Fa Yang

    (Institute of Medicine, Chung Shan Medical University, Taichung 402, Taiwan
    Department of Medical Research, Chung Shan Medical University Hospital, Taichung 402, Taiwan)

Abstract

Prostate cancer is one of the major cancers of the genitourinary tract. High-mobility group box 1 (HMGB1) was suggested as a promising therapeutic target for prostate cancer. In this study, we aim to elucidate the associations of HMGB1 single nucleotide polymorphisms (SNPs) with prostate cancer susceptibility and clinicopathological characteristics. The HMGB1 SNPs rs1412125, rs2249825, rs1045411, and rs1360485 in 579 prostate cancer patients and 579 cancer-free controls were analyzed with real-time polymerase chain reactions (real-time PCR). All of the data were evaluated with SAS statistical software. Our results showed that the HMGB1 rs1045411 T allele genotype was significantly associated with advanced pathologic T stage (odds ratio (OR) = 1.433, 95% confidence interval (CI) = 1.021–2.012; p = 0.037) and pathologic N1 stage (OR = 2.091, 95% CI = 1.160–3.767; p = 0.012), and the rs1360485 polymorphic CT + TT genotype was associated with pathologic Gleason grade group (4 + 5) (OR = 1.583, 95% CI = 1.017–2.462; p = 0.041), pathologic T stage (3 + 4) (OR = 1.482, 95% CI = 1.061–2.070; p = 0.021), and pathologic N1 stage (OR = 2.131, 95% CI = 1.178–3.852; p = 0.011) compared with their wild-type carriers. In conclusion, our results revealed that the HMGB1 SNPs were associated with the clinical status of prostate cancer. The HMGB1 SNPs may have the potential to predict prostate cancer disease progression.

Suggested Citation

  • Ying-Erh Chou & Po-Jen Yang & Chia-Yen Lin & Yen-Yu Chen & Whei-Ling Chiang & Pei-Xuan Lin & Zih-Yun Huang & Matthew Huang & Yung-Chuan Ho & Shun-Fa Yang, 2020. "The Impact of HMGB1 Polymorphisms on Prostate Cancer Progression and Clinicopathological Characteristics," IJERPH, MDPI, vol. 17(19), pages 1-11, October.
    • Handle: RePEc:gam:jijerp:v:17:y:2020:i:19:p:7247-:d:423553
    as

    Download full text from publisher

    File URL: https://www.mdpi.com/1660-4601/17/19/7247/pdf
    Download Restriction: no
    File URL: https://www.mdpi.com/1660-4601/17/19/7247/
    Download Restriction: no
    ---><---

    More about this item

    Keywords

    prostate cancer; HMGB1 ; polymorphism;
    All these keywords.

    JEL classification:

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:gam:jijerp:v:17:y:2020:i:19:p:7247-:d:423553. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: MDPI Indexing Manager (email available below). General contact details of provider: https://www.mdpi.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.